# OnCo record nct06750419 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06750419/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06750419", "NCT06750419" ;
  schema:name "89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study"@en ;
  schema:alternateName "ZIRCON-CP"@en ;
  schema:description "A phase 3 trial of Zirconium-89 girentuximab run by Telix Pharmaceuticals (Innovations) Pty Limited in renal cell carcinoma, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06750419/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06750419> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-11-06" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:technologies <https://onco.cc/technologies/immuno-pet/>, <https://onco.cc/technologies/caix-pet/> ;
  onco:drugs <https://onco.cc/drugs/girentuximab-zr89/> ;
  onco:companies <https://onco.cc/companies/telix/> .